InnoScot Health spinout CardioPrecision has been nominated for a prestigious Scottish Life Sciences Award

Glasgow-based CardioPrecision is a global leader in innovating transcervical access for the treatment of structural heart disease and cardiothoracic interventions – and that status has now been recognised with a nomination in the ‘Innovation - Healthcare Technology’ category of the Scottish Life Sciences Awards.

The event – a black-tie dinner and awards celebration to be held at the National Museum of Scotland in Edinburgh on 16 March – is expected to see over 700 leading players in the global life sciences community in attendance.

CardioPrecision was originally spun out of NHS Greater Glasgow & Clyde and NHS Golden Jubilee in 2007 through InnoScot Health, which was pleased to participate, for the first time since the spin out, in a recent funding round alongside other Scottish based investors. That bridging round of equity investment will allow CardioPrecision to begin roll out of its technology around the world post relaxation of international COVID restrictions.

Executive Chair of InnoScot Health, Graham Watson said: “Our congratulations go to the CardioPrecision team on this entirely merited nomination – a reflection of their remarkable achievements.

“It has been a real pleasure to have had the opportunity of continuing to work closely with the team and to watch their unique platform for a wide range of clinical applications go from strength to strength.

“It is therefore no surprise to us that CardioPrecision’s global ambition and dedication to making patients’ lives better through the development of innovative, less invasive access solutions has now been recognised.

“We wish the team the very best of luck for March where they will rightfully take their place among the best life sciences innovators in Scotland.”

With its CoreVista® devices – developed against the backdrop of the COVID pandemic – proven to be highly effective in Scotland, CardioPrecision took a significant step by announcing its entry into the US market in August last year.

It introduced its unique technology at the prestigious Massachusetts General Hospital in Boston where it was well-received. The US is currently the largest medical device market by value in the world and represents a significant scale up for the company.

CardioPrecision’s wide patent portfolio, and the technology it protects, could potentially be applied to a wide range of cardiothoracic procedures and the company will continue to supplement its suite of innovative devices